Targeting the Bone Marrow Microenvironment

Michele Moschetta, Yawara Kawano, Klaus Podar

Publikation: Beitrag in Buch/Bericht/KonferenzbandKapitel in Buch/Bericht

10 Zitate (Scopus)

Abstract

Unprecedented advances in multiple myeloma (MM) therapy during the last 15 years are predominantly based on our increasing understanding of the pathophysiologic role of the bone marrow (BM) microenvironment. Indeed, new treatment paradigms, which incorporate thalidomide, immunomodulatory drugs (IMiDs), and proteasome inhibitors, target the tumor cell as well as its BM microenvironment. Ongoing translational research aims to understand in more detail how disordered BM-niche functions contribute to MM pathogenesis and to identify additional derived targeting agents. One of the most exciting advances in the field of MM treatment is the emergence of immune therapies including elotuzumab, daratumumab, the immune checkpoint inhibitors, Bispecific T-cell engagers (BiTes), and Chimeric antigen receptor (CAR)-T cells. This chapter will review our knowledge on the pathophysiology of the BM microenvironment and discuss derived novel agents that hold promise to further improve outcome in MM.

OriginalspracheEnglisch
TitelPlasma Cell Dyscrasias
Seiten63-102
Seitenumfang40
Band169
DOIs
PublikationsstatusVeröffentlicht - 2016
Extern publiziertJa

Publikationsreihe

NameCancer Treatment and Research
Band169
ISSN (Print)0927-3042

ASJC Scopus Sachgebiete

  • Onkologie
  • Krebsforschung

Fingerprint

Untersuchen Sie die Forschungsthemen von „Targeting the Bone Marrow Microenvironment“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren